Welcome to our dedicated page for Cumberland Pharmaceuticals news (Ticker: CPIX), a resource for investors and traders seeking the latest updates and insights on Cumberland Pharmaceuticals stock.
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) is a specialty pharmaceutical company whose news flow centers on its portfolio of FDA-approved brands and its clinical development programs. The company focuses on hospital acute care, gastroenterology, and oncology markets, and its announcements often highlight product milestones, commercialization agreements, and study results that affect how its medicines are used in practice.
Recent news has covered developments for Caldolor (ibuprofen) injection, including a permanent CMS J-code associated with a reimbursement price that supports its use as a non-opioid option for managing pain and fever. Cumberland has also reported regulatory approval of its ibuprofen injection product in Mexico through a partnership with PiSA Farmaceutica, reflecting the company’s efforts to expand access to its hospital acute care therapies internationally.
Another recurring theme in CPIX news is the expansion of Vibativ (telavancin) injection. Press releases describe new supply arrangements and group purchasing agreements with organizations such as Vizient and Premier in the United States, as well as the launch of Vibativ in Saudi Arabia through Tabuk Pharmaceutical Manufacturing Company. These updates explain how hospitals and providers can access Vibativ in different configurations and markets.
Cumberland’s news also highlights its ifetroban Phase II clinical programs in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, and Idiopathic Pulmonary Fibrosis, including presentations of trial data and regulatory interactions. In addition, investors can follow revenue updates and quarterly financial results, which break down net revenues by product such as Kristalose, Sancuso, Vibativ, and Caldolor.
For readers tracking CPIX, the news stream provides insight into product-level performance, international partnerships, reimbursement developments, and the progress of late-stage clinical studies. Bookmarking this page can help investors, clinicians, and other stakeholders follow key events affecting Cumberland’s commercial portfolio and pipeline.
Cumberland Pharmaceuticals Inc. (CPIX) announced a national co-promotion agreement with Verity Pharmaceuticals to promote Sancuso, the first FDA-approved patch for preventing chemotherapy-induced nausea and vomiting (CINV). Sancuso releases granisetron through the skin, effective for up to five days when applied before chemotherapy. Verity will leverage its oncology sales organization to enhance Sancuso's market reach following Cumberland's earlier acquisition of its U.S. rights. This partnership aims to expand patient access to Sancuso through shared marketing and sales efforts.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will release its first quarter 2022 financial results and an update on May 10, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET that day for discussion on the results. Interested parties can join via phone or through the company’s website. The company specializes in high-quality prescription products for hospital acute care, gastroenterology, and rheumatology, with a strong portfolio of FDA-approved brands and ongoing clinical programs for ifetroban in various conditions.
Cumberland Pharmaceuticals has launched Vibativ (telavancin) in the Middle East, partnering with Tabuk Pharmaceutical Manufacturing Co. This collaboration grants Tabuk exclusive rights to register and promote Vibativ in Saudi Arabia and Jordan. Vibativ is a once-daily antibiotic indicated for multidrug-resistant infections, particularly effective against MRSA and pneumonia. The partnership aims to enhance Tabuk's anti-infective portfolio and improve patient access to this critical treatment.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) reported its full-year 2021 financial results, with net revenues reaching $36 million and cash flow from operations of $6 million. The company acquired Sancuso®, a drug for preventing chemotherapy-induced nausea and vomiting, enhancing its product portfolio. Total assets stood at $84 million, with total liabilities of $42 million. Adjusted earnings for 2021 were $(1.2 million), or $(0.08) per share, indicating improved performance compared to a net loss of $(5.6 million) in the previous year.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will release its annual 2021 financial results and company update after the market closes on March 8, 2022. A conference call to discuss these results will take place that same day at 4:30 p.m. Eastern Time, accessible by phone and via a live webcast on the company's website. Cumberland focuses on delivering high-quality prescription brands for acute care, gastroenterology, and rheumatology, with a portfolio that includes several FDA-approved products such as Acetadote and Caldolor.
Cumberland Pharmaceuticals (NASDAQ: CPIX) has acquired SANCUSO® (granisetron transdermal patch) from Kyowa Kirin for $13.5 million, with additional milestone payments and royalties up to 10% on U.S. net sales. SANCUSO is the only FDA-approved patch for preventing chemotherapy-induced nausea and vomiting, with U.S. sales exceeding $14 million in 2020. This acquisition allows Cumberland to enhance its oncology portfolio, addressing the needs of the approximately 500,000 Americans undergoing chemotherapy each year.
Cumberland Pharmaceuticals has received FDA approval for expanded labeling of Caldolor, an intravenous ibuprofen formulation, allowing its use in pre-operative administration. This approval aims to reduce post-surgery pain significantly for patients waking up from procedures. The labeling includes details on indications, appropriate patient populations, and clinical study results. A recent study involving 185 patients showed significant pain reduction with Caldolor compared to a placebo over 24 hours post-surgery. This development aligns with the ongoing efforts to manage surgical pain and decrease opioid reliance.
Cumberland Pharmaceuticals (NASDAQ: CPIX) reported a net revenue of $8.1 million for Q3 2021, totaling $27.7 million for the first nine months, reflecting a 1.8% increase year-over-year. The company holds total assets of $87.6 million and $25.8 million in cash, with total liabilities of $41 million. The launch of RediTrex for rheumatoid arthritis and psoriasis was implemented during Q3 2021. Despite the pandemic challenges, Cumberland remains focused on improving patient care and has additional clinical programs for its ifetroban candidate.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) will announce its third quarter 2021 financial results and provide a company update on November 9, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. Eastern Time. The company specializes in branded prescription products for acute care, gastroenterology, and rheumatoid arthritis. Key FDA-approved brands include Acetadote, Caldolor, and Vaprisol, among others. Additionally, Cumberland is developing therapies for conditions like Duchenne Muscular Dystrophy.
Cumberland Pharmaceuticals (NASDAQ: CPIX) has launched its RediTrex (methotrexate) line of pre-filled syringes, designed for treating active rheumatoid arthritis, juvenile idiopathic arthritis, and severe psoriatic arthritis. RediTrex is FDA-approved and offers advantages such as easy handling, accurate dosing, and reduced discomfort. It is more effective and less costly than oral methotrexate, potentially delaying the need for expensive biologics. This injectable option is particularly beneficial for patients with dexterity issues, addressing the challenges of existing administration methods.